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Background: Inadequate response to proton pump inhibitor (PPI) therapy in patients with gastroesophageal reflux
disease (GERD) is reported in up to 40%. Patients with non erosive reflux disease (NERD) have lower response rates
compared to patients with erosive reflux disease (ERD); pH metry contributes to GERD diagnosis and is critical for
proper diagnosis of NERD.
Aim of the study was to assess the need for doubling esomeprazole standard dose (40 mg) for 4 weeks in
PPI naive patients with typical reflux symptoms and diagnosis of GERD based on endoscopy and 48 hours,
wireless pH metry.
Methods: All patients underwent upper GI endoscopy. Symptoms were recorded with a structured questionnaire
(RDQ) and acid exposure was determined by 48 hours, wireless pH monitoring (BRAVO). In case of abnormal acid
exposure, patients received a short term treatment with esomeprazole 40 mg q.d. for 4 weeks. If symptoms persisted,
patients underwent a second pH metry on PPI and the dose was increased to 40 mg b.i.d.
Results: 31 consecutive patients with typical reflux symptoms underwent 48 hours pH monitoring. 22 patients (71%)
had abnormal acid exposure, 9 patients had normal pH metry (29%). Of the 9 patients with normal pH metry, 2 were
found with erosive esophagitis and 7 without endoscopic abnormalities.
24 patients with documented GERD received esomeprazole treatment. 21 patients achieved complete symptom
resolution with 40 mg q.d. after 4 weeks (88%). Only 2 patients required doubling the dose of esomeprazole for
complete symptom resolution, 1 patient remained with symptoms.
Conclusions: Patients with typical reflux symptoms and abnormal acid exposure have a high response rate to
standard dose esomeprazole regardless of whether they have ERD or NERD.
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GERD is defined as a condition which develops when re-
flux of gastric contents causes troublesome symptoms
and/or mucosal lesions in the distal esophagus [1]. The
problems of a symptom-based diagnosis of GERD are
demonstrated by Dent and colleagues who found typical
symptoms in only 49% of the patients [2] with proven
GERD. Nevertheless most guidelines recommend to first
administer an empiric trial of proton pump inhibitors
(PPIs) for patients presenting with typical GERD-related* Correspondence: peter.malfertheiner@med.ovgu.de
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reproduction in any medium, provided the orsymptoms without alarm symptoms (dysphagia, weight
loss) [3].
Erosive reflux disease (ERD) is diagnosed endoscopic-
ally [4,5], however in the absence of erosions, the diag-
nosis of NERD deserves functional testing. This includes
ambulatory pH metry, prolonged pH metry or combined
pH and intraluminal impedance measurements to define
timing, acid exposure time, reflux characteristics as well
as symptom association [3,6,7]. The wireless and pro-
longed 48 hours capsule pH metry has been demon-
strated to exhibit better compliance and patients’
satisfaction and better test accuracy for the diagnosis of
GERD due to the prolonged measurement and frequent
day-to-day variations in the reflux characteristics ofral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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esophagus or missing association between reflux epi-
sodes and patients’ symptoms are defined as functional
heartburn according to ROME III criteria [10].
Adequate acid inhibition with PPI is the current stand-
ard therapy for GERD [11,12]. The efficacy in healing re-
flux esophagitis is very high for PPI with a number
needed to treat of 1.7 (95% CI 1.5-2.1) [13]. Further-
more, PPIs are effective for the symptomatic response in
GERD [14] but their efficacy differs between the sub-
groups of ERD and NERD with a larger proportion of non-
responders in NERD even when standard dose has been
increased to a twice daily dosage [15,16]. We believe that
this is most likely due to an incorrect diagnosis of NERD.
Our study was designed to test whether, and in which
proportion of patients, PPI standard dose is effective in
achieving complete symptom relief if GERD (ERD and
NERD) is properly diagnosed by either abnormal endo-
scopic findings or abnormal acid exposure using 48 hours
pH metry. A secondary aim was to determine the pro-
portion of patients that need the escalation of esomepra-
zole dosage to 40 mg b.i.d for complete symptom relief.
Methods
The study was approved by the institutional ethics committee
at the Otto-von-Guericke University and the German “Bunde-
sinstitut für Arzneimittel und Medizinprodukte” (BfArM),
funded by Astra Zeneca, Wedel, Germany (Protocol No.
GS0205; Eudract No. 2005-000761-19; Title: Control of Symp-
toms and Acid Reflux by Esomeprazole in Patients with
GERD) and conducted according to the ethical guidelines of
the declaration of Helsinki.
Patients’ population
Patients presenting at the outpatients department of
the Department of Gastroenterology, Hepatology andTable 1 Demographic data pH data and endoscopic results fo
assessment
Screening pH negative sympto
n = 31 n = 9
Gender (male/female) 12/19 0/9
Age (mean±SD) 52.4±17.1 years 47.5±3.5 years 5
Endoscopy
NERD 7 (no erosions)
ERD Los Angeles A 2
ERD Los Angeles B
ERD Los Angeles C
Barrett’s Esophagus
DeMeester score ±SD _ 5.5 ± 1.8
- DeMeester [day 1] _ 5.9 ± 2.9
- DeMeester [day 2] _ 4.9 ± 2.4Infectious Diseases with GERD associated symptoms were
evaluated. Only patients without prior PPI medication
were included in the study (PPI naïve). After given their
written informed consent patients were included in the
screening (for demographic details see Table 1).
Objectives and study design
The primary objective was to determine the proportion
of patients that achieve complete symptom relief with
esomeprazole 40 mg q.d. or b.i.d. Complete symptom re-
lief was defined as absence of reflux symptoms during
seven days, as assessed by the self-administered Reflux
Disease Questionnaire (RDQ) and a diary. Secondary,
the response rates for symptomatic response for proper
diagnosed NERD were assessed and related to ERD.
A further objective was to assess the relation between
gastrointestinal symptom pattern and 48 hour acid re-
flux profile during esomeprazole treatment in patients
with incomplete symptom relief.
The study was designed as an open, mono-centric
treatment study with measurement of symptoms and pH
monitoring before and during therapy with esomepra-
zole. The diagnosis of GERD was confirmed by 48 hours
BRAVO pH monitoring and/or erosions during upper
GI endoscopy.
In case of abnormal findings in BRAVO pH monitor-
ing, patients entered a short term treatment (I) with
esomeprazole 40 mg q.d. for 4 weeks. During acid sup-
pressive therapy, symptom severity was again assessed
by RDQ and a symptom diary. Complete symptom relief
was defined as no GERD symptoms during the last
7 days as documented in the diary and in the RDQ
questionnaire.
In case of persisting symptoms, the patients under-
went a second diagnostic EGD and functional testing,
followed by escalating dosage (II) with esomeprazoler patients before therapy with esomeprazole at baseline
m relief 40 mg q.d. symptom relief 40 mg b.i.d. persistence
n = 19 n = 2 n = 1
9/10 2/0 1/0






26.9 ± 3.9 20.9 ± 15.7 30.3
28.2 ± 4.8 21.6 ± 19.8 23.2
25.6 ± 3.9 10.7 ± 3.5 34.8
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was evaluated under escalating dosage as described be-
fore (Figure 1).
The study medication was to be ingested 30 minutes
before breakfast (I) and dinner (I, II) with 100 ml of
table water.
Esophagogastroduodenoscopy (EGD)
After an overnight fast, all patients underwent EGD
under intravenous conscious sedation (midazolam 2–
5 mg) using a standard videogastroscope (GIF Q160,
Olympus Optical Europe, Hamburg, Germany). Endo-
scopic esophageal landmarks were defined as the gastro-
esophageal junction with the beginning of the gastric
folds and the Z-line as the squamocolumnar junction.
Erosive esophagitis was characterized according to Los
Angeles classification [4].
NERD was defined as normal appearing GEJ and ab-
normal acid exposure during 48 hours pH metry.
Wireless 48 hours BRAVO™ pH monitoring
Ambulatory pH monitoring was performed over 48 hours
using the wireless BRAVO capsule pH monitoring device
(Medtronic, Minneapolis/GIVEN). Capsules were cali-
brated at pH 1.0 and 7.0 by submersion in buffer solu-
tions (Medtronic/GIVEN) according to the product
information. During EGD the gastroesophageal junction
(GEJ) was visualized and the capsule was attached at the
esophageal mucosa at 6 cm above GEJ with vacuum suc-
tion of 700 mmHg for 2 minutes. The correct placement
of the capsule was confirmed endoscopically. The pHFigure 1 Study design and disposition of patients.data was transmitted by the capsule to a recording de-
vice with 433 Hz and a sampling interval of 6 seconds.
The patients were asked to carry or keep the recording
device within a maximum distance of 100 cm maximum
from their bodies. The patients were instructed to follow
their normal daily activities and diet. During the period
of 48 hours, meal time, sleep disturbances, supine and
upright positions were marked in a patients’ diary.
After 48 hours patients returned to hospital and the data
were downloaded from the recording device. The record-
ings were completed by entering the diary information
manually and analyzed based on the manufacture’s soft-
ware (POLYGRAM NET™ Version 14.1.1322.287).
Total numbers of acid episodes, acid exposure time
(AET, pH < 4) and DeMeester score were analyzed for
day 1 and day 2 separately as well as for 48 hours in
total. Acid exposure time ≥ 4.2% and/or a DeMeester
score ≥ 13.9 were considered abnormal [6].
Evaluation of symptoms by validated reflux disease
questionnaire (RDQ) and patient’s diary
Complete symptom relief was defined as absence of
GERD-related symptoms during the last 7 days as docu-
mented by RDQ (<5 points) and a symptom-assessing
diary. The self-administered patient’s diary documented
the severity of symptoms on 7 days before and under
treatment with esomeprazole. The diary graded heart-
burn objectively on a 5 point Likert-scale for each day as
used in the EXPO study [17].
The RDQ was designed to grade different reflux symp-
toms during the last seven days. The RDQ is a self-
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to report the frequency and severity of their upper
gastrointestinal symptoms. There are three subscales
that evaluate regurgitation, heartburn, and dyspepsia.
Response options were also scaled as Likert-type with
scores ranging from 0 to 5 for frequency and severity.
Each subject’s score was calculated as the mean of item
responses with higher scores indicating more severe or
frequent symptoms [18,19].
Statistical analysis
According to the results of the EXPO study, where
91.1% of patients experienced had complete symptom
relief after four week treatment with esomeprazole
40 mg orally the sample size was calculated. With focus
on complete symptom relief, the hypothesis H0
complete symptom relief < =68% vs. H1 complete symp-
tom relief > 85% was tested by a one-sided binomial test,
which will have a power of 80% (type-I-error 5%). 40
patients were calculated as the requested sample size.
All data entered into a database using the Microcal
Origin™ 5.0 program package (Northhampton, MA,
USA) and SPSS© 12.0. Data is expressed as mean and
95%-CI (confidence intervals), if not stated otherwise.
For statistical analysis (pre- and post-treatment) para-
metric T-test was used. All test were applied two-sided
with a level of significance of P < 0.05.Results
Patients’ characteristics
A total of 40 patients with predominantly female gender
were included in the screening phase of the study (mean
age 52 years; range: 18–79 years) (Table 1).
31 patients met the inclusion criteria with either endo-
scopic findings of erosive reflux disease (n = 2), abnormal
pH metry (NERD n = 7) or both (n = 15). In 7 patients
with normal appearing gastroesophageal junction (all
female), GERD was excluded by normal results in BRAVO
pH monitoring (Table 2).
There was a withdrawal of 9 patients for different rea-
sons: 5 patients did not complete neither questionnaire
nor diary; one patient stopped the study medication be-
cause of an newly appeared exanthema; 3 patients pre-
sented with technical problems in BRAVO capsule
testing (1 patient suffered from severe chest pain thatTable 2 Diagnosis and response to esomperazole 40 mg q.d.
diagnosis
abnormal pH metry only (NERD)
ERD and abnormal pH metry [pH +]
ERD and normal pH metry [pH -]
normal endoscopy and normal ph metry [pH-]required endoscopic removal of the capsule; 2 patients
documented an early drop off the capsule).
Control of symptoms and acid reflux by standard dose
and doubled standard dose of esomeprazole
Finally, 24 patients entered the treatment phase. Endoscopic
diagnosis revealed 7 patients with non-erosive reflux disease
(NERD), 15 patients with erosive reflux disease (ERD) and 2
patients with newly diagnosed short segment Barrett’s
esophagus without dysplasia (Tables 1, 2).
After 4 weeks of treatment with esomeprazole 40 mg
q.d., 21 (88%) patients achieved complete symptom re-
lief. 2 patients achieved symptom relief after escalating
dosage of esomeprazole to 40 mg b.i.d. (8%), but only 1
patient presented with persisting symptoms even after
escalating dosage. In this patient, pH metry revealed an
even unchanged cluster of pH metry during esomepra-
zole treatment (Figure 1).
No differences were obtained between patients with
NERD and ERD (Figure 2) and no substantial differences
were found between day 1 and day 2 of pH analysis
(Table 1).
Relief of symptoms documented RDQ and patient’s diary
Patients with complete relief of symptoms according to
RDQ and diary are shown in Figure 3. The calculated RDQ
means pre- and post PPI therapy differed 6.3–times in total
(19.1 [14.07 – 24.02] vs. 3.2 [0.51 – 5.4]; p < 0.0001), 8.2-
times for heartburn (6.5 [4.5 – 8.4] vs. 0.8 [0.19 – 1.78]; p
< 0.0001), 5.1-times for regurgitation (7.2 [4.7 – 9.63] vs.
1.4 [0.08 – 2.75]; p < 0.0001) and 4.2-times for dyspepsia
(5.4 [3.36 – 7.47] vs. 1.3 [0.17 – 2.3]; p < 0.0001). Similar to
the RDQ, the diaries were evaluated for the patients
included and documented a 3.9-fold reduction of the mean
value (17.2 [13.9 – 20.49] vs. 4.4 [3.3 – 5.1]; p < 0.0001;
Figure 4).
Discussion
The main finding of this study is that patients with typ-
ical reflux symptoms and abnormal acid exposure have a
high response rate to standard esomeprazole regardless
of whether they have ERD or NERD. Two thirds (22/31)
of patients with typical GERD-related symptoms had an
abnormal acid exposure in esophageal BRAVO pH
metry. Including 2 patients with erosive changes butfor 4 weeks





Figure 2 Therapeutic response to esomeprazole 40 mg o.d. in
patients with NERD and ERD.
Figure 4 Mean severity of symptoms at screening and after
4 weeks of treatment with esomeprazole 40 mg q.d. according
to patients’ diary.
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ment in our study.
88% of this well selected patient group achieved
complete symptom relief on esomeprazole standard dose
for 4 weeks. Symptomatic response was similarly obtained
in patients with ERD and NERD (Table 2; Figure 2). The
claim that patients with NERD would have a worse re-
sponse to PPI is therefore most likely due to the inclusion
of patients without abnormal gastroesophageal reflux in
previous studies. Misdiagnosis of GERD – NERD in par-
ticular – might also explain reasonably the high PPI failure
rate in previously published data. Weijenborg and collea-
gues systematically reviewed previous outcome studies
and found only 2 studies defining NERD by both negative
endoscopy and a positive pH-test. In contrast to poorFigure 3 Mean heartburn, regurgitation, dyspepsia and total RDQ scoresponse rates in empirical treated or endoscopy-negative
patients, the pooled estimate rate of complete relief of
heartburn after 4 weeks of for those accurately diagnosed
NERD was 0.73 (95% CI 0.69-0.77) and comparable to
patients with ERD [20]. This clinical data indicates to
careful asses the diagnosis of NERD and differentiate espe-
cially from functional heartburn to predict a therapeutic
success of current PPI therapy.
We excluded patients with normal acid exposure as
there is no rationale for PPI treatment. This category of
patients is likely to account for the frequent reports with
up to 30-40% PPI failure to standard dose [15,21]. Inres at screening and after 4 weeks of treatment.
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60% [22]. For patients not responding to PPI in presence
of typical symptoms, functional testing is performed to
test the initial diagnosis and to further investigate for
conditions that might explain PPI refractoriness. Among
them, persistent acid or non-acid reflux episodes have
been reported to be responsible for incomplete symptom
relief [6,23-26].
In a further subset of patients, reflux symptoms may be
unrelated to reflux episodes at all and related to a func-
tional syndrome (functional heartburn) [27]. Although un-
able to determine the proportion of “non acidic” reflux
episodes by BRAVO pH metry, our study reemphasizes
the importance of the patients’ interview and interpret-
ation of symptoms to distinguish between acid-related
symptoms and functional disorders that often overlap and
requires different medical treatment [27,28].
For patients not responding to PPI, pH metry should
be considered to confirm the diagnosis of abnormal gas-
troesophageal reflux. Mechanisms involved in symptom
generation or perpetration are either hypersensitivity to
visceral stimuli or weakly acidic reflux episodes, a fast
hepatic metabolism of PPIs [29] or duodenogastroeso-
phageal reflux (DGER) [15,30]. Intestinal proteases in
the refluxate and interaction with epithelial protease-
activated receptors are also involved in the pathogenesis
of mucosal inflammation in GERD pathogenesis [31,32].
The shortcomings of the study are the missing control
group and the small sample size. This was mainly due to
the inclusion criteria of PPI naive patients in a referral
centre. As calculated before, the recruitment was fina-
lized after having screened 40 patients.
In spite of the small sample size, the results indicate
daily clinical practice. Nevertheless, our study has the
true advantage of having included truly PPI-naive
patients, a fact that is very hard in routine clinical prac-
tice, as most physicians administer PPI very quickly
based on current guidelines. However, this “aggressive”
approach might need to be rethought, as we believe that
many patients receiving PPI do not suffer from NERD
or ERD, and thus being over treated. Thus, a careful ini-
tial assessment of symptoms combined with functional
testing may identify the patients who respond well to
PPI therapy. This fact needs to be reconsidered in the
interpretation of many clinical trials concerning re-
sponse to PPI therapy, especially in NERD [20].
Conclusion
PPI naïve patients with characteristic GERD-related
symptoms and abnormal findings in pH metry had an
excellent response to standard dose esomeprazole. Due
to the small sample size of our study it cannot be con-
cluded, but patients with NERD diagnosed with pH
metry and endoscopy did not differ in their responserates to esomeprazole in comparison with ERD. This
corresponds to the systematic review cited above and
responds to the studies investigating the PPI test, and
documented symptom relief in up to 90% in case of
pathological acid exposure [33,34].
29% of the patients in our study suffered from typical
GERD-related symptoms but had no abnormal acid ex-
posure in 48 hours pH metry, predominantly with un-
suspicious results in EGD (no erosions). This may partly
explain the high proportion of PPI non-responsiveness
in the literature, since the patients may all have been
grouped as NERD [21].
For non-responders with abnormal 48 hours pH
metry, in clinical practice it may be appropriate to escal-
ate PPI to double standard dose before embarking in
functional testing (MII-pH) and seek for other mechan-
isms in GERD pathogenesis.
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